96. Obesity & rare disease, Patrick Kleyn, SVP and Head of Translational R&D,Rhythm Pharmaceuticals

96. Obesity & rare disease, Patrick Kleyn, SVP and Head of Translational R&D,Rhythm Pharmaceuticals

Patrick Kleyn joined Rhythm in 2018 with over 25 years’ experience in human genetics and genomics, and he was named as head of TRAD in 2021. Prior to joining Rhythm, Patrick has held leadership roles in academia, biotech and large pharmaceutical companies, as his work has focused on the application of genomic technologies for drug and biomarker discovery and development. He began his career at Millennium Pharmaceuticals initially working on obesity target discovery and ultimately leading the genomics organization. He subsequently served as Chief Scientific Officer at Gemini Genomics and as Head of Scientific Planning at the Broad Institute during its inception and launch. He left the Broad to co-found Ligon Discovery and subsequently joined EMD Serono as the Head of External Innovation at its Boston site. Patrick earned his bachelor’s of Natural Sciences at Cambridge University, his Ph.D. in human genetics at University College London and carried out postdoctoral research in neuromuscular diseases at Columbia University.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(261)

Ardelyx Leaders Mike Raab & Laura Williams on Building Biotech Around Patients

Ardelyx Leaders Mike Raab & Laura Williams on Building Biotech Around Patients

Synopsis: While biotech is increasingly measured by clinical milestones and financial outcomes, Rahul Chaturvedi welcomes two leaders who argue that true success begins and ends with patients. In th...

10 Jun 41min

Acadia CEO Catherine Owen Adams on Neurodegeneration, AI & Building Biotech Vision

Acadia CEO Catherine Owen Adams on Neurodegeneration, AI & Building Biotech Vision

Synopsis: At the intersection of personal mission and biotech leadership, Rahul Chaturvedi sits down with Catherine Owen Adams, CEO of Acadia Pharmaceuticals, for a deeply personal and strategically...

13 Mai 33min

Barry Quart, CEO of Connect Biopharma, on Asthma Innovation & Biotech Leadership

Barry Quart, CEO of Connect Biopharma, on Asthma Innovation & Biotech Leadership

Synopsis: This episode is proudly sponsored by Quartzy. At a time when biotech innovation is being reshaped by science, capital, and global dynamics, Alok Tayi sits down with Barry Quart, CEO of Co...

16 Apr 23min

Adial CEO Cary Claiborne on Treating Alcohol Addiction with Genetics

Adial CEO Cary Claiborne on Treating Alcohol Addiction with Genetics

Synopsis: Addiction is often misunderstood as a failure of willpower—but emerging science increasingly shows it may be deeply rooted in biology. In this episode of Biotech 2050, recorded during JPM...

6 Mar 14min

Sheila Gujrathi, MD on Leadership, Biotech Innovation & The Mirror Effect for Women Leaders

Sheila Gujrathi, MD on Leadership, Biotech Innovation & The Mirror Effect for Women Leaders

Synopsis: This episode is proudly sponsored by Quartzy. Physician-scientist, biotech founder, and leadership advocate Sheila Gujrathi, MD joins Rahul Chaturvedi on the Biotech 2050 Podcast for a po...

5 Mar 39min

Fred Aslan, Artiva CEO, on Cell Therapy’s Next Wave, RA Trials & Scalable NK Platforms

Fred Aslan, Artiva CEO, on Cell Therapy’s Next Wave, RA Trials & Scalable NK Platforms

Synopsis: At the heart of JPM 2026’s biotech buzz, Alok Tayi sits down with Fred Aslan, CEO of Artiva, to explore how bold platform bets, scalable cell therapies, and autoimmune breakthroughs could ...

11 Feb 25min

Michelle Werner, CEO of Alltrna, on tRNA Platforms, Rare Disease & Drug Innovation

Michelle Werner, CEO of Alltrna, on tRNA Platforms, Rare Disease & Drug Innovation

Synopsis: At JPM 2026 in San Francisco, Alok Tayi welcomes Michelle Werner, CEO of Alltrna, to Biotech 2050 for a powerful conversation at the intersection of personal mission, platform biology, and...

10 Feb 26min

Brian Hilberdink on Boehringer’s U.S. Growth, AI & Pharma’s Next Frontier

Brian Hilberdink on Boehringer’s U.S. Growth, AI & Pharma’s Next Frontier

Synopsis: From managing a theme park in Canada to leading the U.S. business of one of the world’s largest privately held pharma companies, Brian Hilberdink’s journey is anything but conventional. Li...

28 Jan 21min

Populært innen Vitenskap

fastlegen
tingenes-tilstand
rekommandert
liberal-halvtime
sinnsyn
jss
villmarksliv
forskningno
tomprat-med-gunnar-tjomlid
fjellsportpodden
dekodet-2
rss-kunstig-intelligens-med-elisabeth-maren-og-morten
rss-rekommandert
nevropodden
smart-forklart
rss-paradigmepodden
rss-nysgjerrige-norge
abid-nadia-skyld-og-skam
abels-tarn
rss-overskuddsliv